Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes

Therapeutic Drug Monitoring

Volumn 32, Issue 2, 2010, Pages 206-215

  Concheiro, Marta ^a   Jones, Hendreé E ^b   Johnson, Rolley E ^b,c   Choo, Robin ^d   Shakleya, Diaa M ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RECKITT BENCKISER   (United Kingdom)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Buprenorphine; In utero drug exposure; Neonatal Abstinence Syndrome; Opioid dependence; Placenta

Indexed keywords

BUPRENORPHINE; COCAINE; DRUG METABOLITE; METHADONE; NORBUPRENORPHINE; NORBUPRENORPHINE GLUCURONIDE; OPIATE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; DOUBLE BLIND PROCEDURE; DRUG DISPOSITION; DRUG DISTRIBUTION; EUROPE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MECONIUM; NEWBORN; OPIATE ADDICTION; OUTCOME ASSESSMENT; PLACENTA; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; WITHDRAWAL SYNDROME; COMPARATIVE STUDY; DRUG EFFECTS; FETOMATERNAL TRANSFUSION; MALE; METABOLISM; OPIOID-RELATED DISORDERS; PHYSIOLOGY; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; BUPRENORPHINE; COHORT STUDIES; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MATERNAL-FETAL EXCHANGE; OPIOID-RELATED DISORDERS; PLACENTA; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950280895     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181d0bd68     Document Type: Article

References (38)

1. Drug Addiction Treatment Act 2000, p. 111, STAT. 1101.
2. Lejeune C, Simmat-Durand L, Gourarier L, et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006;82:250-257.
3. Fischer G. Treatment of opioid dependence in pregnant women. Addiction. 2000;95:1141-1144.
4. Dunlop A, Panjari M, O'Sullivan H, et al. Clinical Guidelines for the Use of Buprenorphine in Pregnancy. Fitzroy, Victoria: Turning Point Alcohol and Drug Centre; 2003.
5. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat. 2008; 35:245-259.
6. Iribarne C, Picart D, Dreano Y, et al. Involvement of cytochrome P450 3A4 in n-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997;60:1953-1964.
7. King CD, Green MD, Rios GR, et al. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP- glucuronosyltransferase 1.1. Arch Biochem Biophys. 1996;332:92-100.
8. Rios G, Tephly T. Inhibition and active sites of UDP-glucuronosyl- transferases 2B7 and 1A1. Drug Metab Dispos. 2002;30:1364-1367.
9. Rouguieg K, Picard N, Sauvage F-L, et al. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010;38:40-45.
10. Pasanen M. The expression and regulation of drug metabolism in human placenta. Adv Drug Deliv Rev. 1999;38:81-97.
11. Deshmukh SV, Nanovskaya TN, Ahmed MS. Aromatase is the major enzyme metabolizing buprenorphine in human placenta. J Pharmacol Exp Ther. 2003;306:1099-1105.
12. Pasanen M, Pelkonen O. The expression and environmental regulation of P450 enzymes in human placenta. Crit Rev Toxicol. 1994;24: 211-229.
13. Kitawaki J, Inoue S, Tamura T, et al. Increasing aromatase cytochrome P-450 level in human placenta during pregnancy: studied by immuno-histochemistry and enzyme-linked immunosorbent assay. Endocrinology. 1992;130:2751-2757.
14. Collier AC, Ganley NA, Tingle MD, et al. UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem Pharmacol. 2002;63:409-419.
15. Pelkonen O. Biotransformation of xenobiotics in the fetus. Pharmacol Ther. 1980;10:261-281.
16. Hakkola J, Pelkonen O, Pasanen M, et al. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol. 1998;28:35-72.
17. Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997;247:625-634.
18. Garland M, Abildskov KM, Taylor S, et al. Fetal morphine metabolism and clearance are constant during late gestation. Drug Metab Dispos. 2006;34:636-646.
19. Schinkel A, Jonker J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003; 55:3-29.
20. Nekhayeva IA, Nanovskaya TN, Hankins GD, et al. Role of human placental efflux transporter P-glycoprotein in the transfer of buprenor-phine, levo-alpha-acetylmethadol, and paclitaxel. Am J Perinatol. 2006; 23:423-430.
21. Nanovskaya T, Deshmukh S, Brooks M, et al. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther. 2002;300: 26-33.
22. Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekel-man RA, Friedman SB, Nelson NM et al, eds. Primary Pediatric Care. St. Louis: Mosby Year Book; 1992:1367-1378.
23. Kacinko S, Jones H, Johnson R, et al. Correlations of Maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther. 2008;84: 604-612.
24. Marquet P, Lavignasse P, Gaulier J, et al. Case study of neonates born to mothers undergoing buprenorphine maintenance treatment. In: Kintz P, Marquet P, eds. Buprenorphine Therapy of Opiate Addiction. Totowa, NJ: Humana Press; 2002:125-135.
25. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79: 1-10.
26. Signorini DF, Leung O, Simes RJ, et al. Dynamic balanced randomization for clinical trials. Stat Med. 1993;12:2343-2350.
27. Mechoulam R, Peters M, Murillo-Rodriguez E, et al. Cannabidiol-recent advances. Chem Biodivers. 2007;4:1678-1692.
28. de Castro A, Concheiro M, Shakleya D, et al. Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry. J Anal Toxicol. 2009;33: 243-252.
29. Concheiro M, Jones H, Johnson RE, et al. Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women. J Chromatogr B. 2010;878:13-20.
30. Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984;12: 577-581.
31. Garcia-Algar O, Lopez-Vilchez MA, Martin I, et al. Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Clin Toxicol (Phila). 2007;45: 295-298.
32. Martin I, Lopez-Vilchez MA, Mur A, et al. Neonatal withdrawal syndrome after chronic maternal drinking of mate. Ther Drug Monit. 2007;29:127-129.
33. Garcia-Algar O, Vall O, Alameda F, et al. Prenatal exposure to arecoline (areca nut alkaloid) and birth outcomes. Arch Dis Child Fetal Neonatal Ed. 2005;90:F276-F277.
34. Luck W, Nau H, Hansen R, et al. Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. Dev Pharmacol Ther. 1985;8:384-395.
35. Casanova OQ, Lombardero N, Behnke M, et al. Detection of cocaine exposure in the neonate. Analyses of urine, meconium, and amniotic fluid from mothers and infants exposed to cocaine. Arch Pathol Lab Med. 1994; 118:988-993.
36. Lozano J, Garcia-Algar O, Vall O, et al. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther Drug Monit. 2007; 29:711-734.
37. Zharikova O, Deshmukh S, Kumar M, et al. The effect of opiates on the activity of human placental aromatase/CYP19. Biochem Pharmacol. 2007;73:279-286.
38. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996;6:1-42.